PLX PHARMA INC (PLXP) Stock Price & Overview
NASDAQ:PLXP • US72942A1079
Current stock price
The current stock price of PLXP is 0.087 USD. Today PLXP is down by -27.8%. In the past month the price decreased by -43.51%. In the past year, price decreased by -97.52%.
PLXP Key Statistics
- Market Cap
- 2.535M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.02
- Dividend Yield
- N/A
PLXP Stock Performance
PLXP Stock Chart
PLXP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PLXP. When comparing the yearly performance of all stocks, PLXP is a bad performer in the overall market: 99.11% of all stocks are doing better.
PLXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLXP. PLXP may be in some trouble as it scores bad on both profitability and health.
PLXP Earnings
PLXP Forecast & Estimates
6 analysts have analysed PLXP and the average price target is 11.22 USD. This implies a price increase of 12796.55% is expected in the next year compared to the current price of 0.087.
For the next year, analysts expect an EPS growth of 36.14% and a revenue growth -57.24% for PLXP
PLXP Groups
Sector & Classification
PLXP Financial Highlights
Over the last trailing twelve months PLXP reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 68.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PLXP Ownership
PLXP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.05 | 855.344B | ||
| JNJ | JOHNSON & JOHNSON | 20.21 | 566.915B | ||
| MRK | MERCK & CO. INC. | 22.35 | 282.297B | ||
| PFE | PFIZER INC | 8.97 | 153.415B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9 | 117.056B | ||
| ZTS | ZOETIS INC | 16.28 | 48.828B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.166B | ||
| VTRS | VIATRIS INC | 5.3 | 15.198B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.23 | 11.922B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.026B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.799B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.144B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.6 | 4.084B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PLXP
Company Profile
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
Company Info
IPO: 2014-03-13
PLX PHARMA INC
9 Fishers Ln Ste E
Sparta NEW JERSEY 07871 US
CEO: Natasha Giordano
Employees: 16
Phone: 17138421249.0
PLX PHARMA INC / PLXP FAQ
Can you describe the business of PLX PHARMA INC?
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
Can you provide the latest stock price for PLX PHARMA INC?
The current stock price of PLXP is 0.087 USD. The price decreased by -27.8% in the last trading session.
What is the dividend status of PLX PHARMA INC?
PLXP does not pay a dividend.
How is the ChartMill rating for PLX PHARMA INC?
PLXP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about PLX PHARMA INC (PLXP) stock?
6 analysts have analysed PLXP and the average price target is 11.22 USD. This implies a price increase of 12796.55% is expected in the next year compared to the current price of 0.087.
Can you provide the sector and industry classification for PLX PHARMA INC?
PLX PHARMA INC (PLXP) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for PLXP stock?
PLX PHARMA INC (PLXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).